Results 261 to 270 of about 14,398,598 (290)

Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas

Future Oncology, 2022
Valentina Gambardella, Martin Wermke, Taofeek K. Owonikoko   +2 more
exaly  

TRISPECIFIC T CELL ENGAGERS

2021
KAROW MARGARET, YAU RICHARD, SHENG JACKIE   +2 more
openaire   +4 more sources

Bispecific T cell engagers

2021
KAROW MARGARET, YAU RICHARD, SHENG JACKIE   +2 more
openaire   +4 more sources

Top bar navigation

Frontiers in Immunology, 2023
Zhigang Tian, Haoyu Sun
exaly  

Tumor and T cell engagement by BiTE.

Discovery medicine, 2014
Cancer immunotherapy attempts to exploit the capability of the immune system to attack malignant cells. Recent results suggest that clinical responses in patients point to this new mechanism as potentially beneficial in harnessing the immune system for combating established malignancies.
openaire   +1 more source

A PD-L1xCD3 bispecific nanobody as a novel T-cell engager in treating PD-L1 overexpression melanoma

Molecular Immunology, 2023
Fuqiu Li, Baihui Shan
exaly  

T-cell engagers in rheumatology

Best Practice & Research Clinical Rheumatology
Alberto Nordmann-Gomes, Leila Khalili, Stephen Wax, Anca Askanase   +3 more
openaire   +1 more source

Mechanistic prediction of first-in-human dose for bispecific CD3/EpCAM T-cell engager antibody M701, using an integrated PK/PD modeling method

European Journal of Pharmaceutical Sciences, 2021
Dongyang Liu, Tianyan Zhou, Junsheng Xue
exaly  

Characterization of an Anti-CD70 Half-Life Extended Bispecific T-Cell Engager (HLE-BiTE) and Associated On-Target Toxicity in Cynomolgus Monkeys

Toxicological Sciences, 2022
Tod A Harper, Olivier Nolan-Stevaux, Majk Kvesic   +2 more
exaly  

Development of an antibody-like T-cell engager based on VH-VL heterodimer formation and its application in cancer therapy

Biomaterials, 2021
Nayoung Kim, Keehoon Jung, Ho Min Kim
exaly